ArticleJournal of cachexia, sarcopenia and muscle2025
Association Between Sarcopenia and the Long-Term Risk of Intervertebral Disc Degeneration.
Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sarcopenic obesity is associated with more severe functional impairment and lumbar degeneration in patients with degenerative lumbar spinal stenosis.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Association Between Sarcopenia and the Long-Term Risk of Intervertebral Disc Degeneration.Journal of cachexia, sarcopenia and muscle · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundSarcopenia and intervertebral disc degeneration (IDD) are both highly prevalent among the elderly and have a substantial impact on their quality of life. However, the association between sarcopenia and IDD remains unclear. This study aimed to investigate whether sarcopenia is independently associated with an increased risk of IDD in middle-aged and older adults, using prospective data from the UK Biobank.
methodsA total of 378 773 participants from the UK Biobank were included and categorized into three groups based on the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria: normal, probable sarcopenia and confirmed sarcopenia. The association between sarcopenia and IDD was examined using Kaplan-Meier survival analysis and Cox proportional hazards models. Sensitivity analyses included subgroup analyses to assess the robustness of findings and interaction tests to explore potential effect modifiers.
resultsThe median age of participants was 59 years, with females accounting for 54.8% of the cohort. Over a median follow-up duration of 171 months, 10 585 participants developed IDD. In unadjusted Cox regression analyses, compared to the normal group, the hazard ratios (HRs) for IDD were 1.51 (95% CI: 1.41-1.61) in the probable sarcopenia group and 1.47 (95% CI: 1.14-1.90) in the confirmed sarcopenia group. After adjusting for multiple covariates, the corresponding HRs were 1.35 (95% CI: 1.26-1.44) and 1.41 (95% CI: 1.10-1.80), respectively. These associations remained consistent across subgroup analyses. Notably, in BMI-stratified analyses, individuals with sarcopenia and a BMI > 25 had a higher risk of IDD (HR: 1.88; 95% CI: 1.31-2.71) compared to those with BMI ≤ 25 (HR: 1.51; 95% CI: 1.06-2.16), with a significant interaction (p < 0.001).
conclusionsSarcopenia is associated with an increased risk of IDD, particularly in overweight or obese individuals. Regular assessment of muscle strength and mass, along with promoting physical activity and adequate nutritional interventions in ageing populations, may help prevent sarcopenia and delay the onset of IDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.